Table 2.

Treatment-emergent adverse events.

		Group A (n=107)	Group B (n=104)
Any TEAEa,b		42 (39.3)	38 (36.5)
Any TEAE occurring in ≥2% of patients
	Arthralgia	8 (7.5)	12 (11.5)
	Upper respiratory tract infection	7 (6.5)	2 (1.9)
Any serious TEAEsc		5 (4.7)	1 (1.0)
Any TEAE leading to death		0	0
Any TEAE leading to discontinuation of Jawboned		1 (0.9)	0
Any TEAE leading to discontinuation of OA GOd,e		1 (0.9)	—

^aTEAE: treatment-emergent adverse events.

^bAll TEAEs were mild to moderate in severity.

^cSerious AEs included upper respiratory tract infection, transient ischemic attack, large intestine perforation, arthralgia and worsening OA, each in one patient in Group A and cholecystitis in one patient in Group B.

^dSame patient discontinued both devices; the TEAE leading to discontinuation was worsening OA.

^eOA: osteoarthritis.